Investment Rating - The report does not provide specific investment ratings for the sub-industries within the pharmaceutical sector [3]. Core Insights - The life sciences upstream sector has experienced a significant recovery since September 24, 2024, with a 60% increase in the index, outperforming the pharmaceutical and biotechnology sectors by 40 percentage points [4][23]. - The sector is currently in a rebound phase after undergoing a clearing phase from mid-2022 to late 2024, characterized by supply-demand imbalances and subsequent recovery [20][23]. Supply Side Summary - The supply side is witnessing a turning point, with local products continuously upgrading to mid-to-high-end levels, aiming for global leadership [5]. - The overall capital expenditure depreciation has dropped to its lowest level in nearly six years, indicating a recovery in the supply chain [29]. - Companies are experiencing a gradual recovery in gross profit margins, with some, like Aladdin and Nanmo Biology, showing signs of improvement after hitting lows [34]. Demand Side Summary - Research institutions and large pharmaceutical companies are steadily increasing their R&D expenditures, with improved financing potentially stimulating high growth in smaller pharmaceutical companies [6]. - The recognition of domestic brands is increasing, accelerating the process of replacing foreign products, particularly in protein and culture media categories [6]. Related Companies - **Aopumai**: A leading domestic brand in culture media, with a comprehensive layout in "culture media + CRO + CDMO" [8]. - **Aladdin**: A domestic high-end research reagent brand, expected to contribute additional growth from overseas [8]. - **Baipusais**: A leading domestic player in recombinant proteins, with a turning point in performance [8]. - **Nuowei Zhan**: A leader in molecular biological reagents, benefiting from the domestic replacement trend [8]. - **Jian Kai Technology**: A leading domestic PEG company, with new product releases expected to open up growth space [8]. - **BGI Genomics**: Focused on domestic markets while expanding globally, optimistic about accelerating domestic replacements [8].

Group 1 - Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd. and Wuhan Changying Tongguang Technology Co., Ltd. have received shareholder approval for their asset purchase proposals, marking a significant step in their merger and acquisition processes [1] - Since the release of the "Eight Measures for Deepening the Reform of the Sci-Tech Innovation Board," the number of M&A transactions on the Sci-Tech Innovation Board has reached 100, indicating increased market activity and supporting high-quality development for listed companies [1] - The total disclosed transaction amount for these 100 M&A deals exceeds 24.7 billion yuan, with 39 new M&A transactions disclosed this year alone [1] Group 2 - Companies are utilizing various funding methods such as private placements, directed convertible bonds, and bank loans to enhance capital efficiency for acquisitions [2] - The 100 M&A transactions are primarily industrial mergers, focusing on companies within the same industry or related upstream and downstream sectors, which helps enhance product offerings and expand customer bases [2] - For instance, Xidi Microelectronics Group plans to acquire 100% of Shenzhen Chengxin Micro Technology Co., Ltd. to fill technology gaps in the AC-DC chip sector [2] Group 3 - Sci-Tech Innovation Board companies are also acquiring overseas mature enterprises to enhance international presence, with 15 overseas acquisition deals disclosed since the "Eight Measures" [3] - Acquisitions of unprofitable companies are aimed at strengthening supply chains, with 27 such deals reported since the "Eight Measures," including Shanghai Silicon Industry Group's acquisition of stakes in its subsidiaries to control the 300mm silicon wafer supply chain [3]

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86- 21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 HKRI Taikoo Hui Shanghai, PRC 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 致：上海奥浦迈生物科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席上海奥浦迈 生物科技股份有限公司（以下简称"公司"）2024 年年度股东大会（以下简称"本 次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集会议人员 的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》 《中华人民共和国证券法》 （以下简称"《公司章 程》"）的规定出具。 本法律意见书仅就本次股东大会的召集和召开程序、出席会议 ...

重要内容提示： ?会议召开时间：2025 年 5 月 27 日（星期二）下午 13:00-14:00 ?会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 证券代码：688293 证券简称：奥浦迈 公告编号：2025-039 上海奥浦迈生物科技股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ?会议召开方式：上证路演中心网络互动 ?投资者可于 2025 年 5 月 20 日（星期二）至 5 月 26 日（星期一）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@opmbiosciences.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）已于 深入地了解公司 2025 年第一季度的经营成果、财务状况，公司计划于 2025 年 5 月 27 日（星期二）下午 13:00-14:00 举行 202 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-039 上海奥浦迈生物科技股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 27 日（星期二）下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 5 月 20 日（星期二）至 5 月 26 日（星期一）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@opmbiosciences.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 （三）会议召开方式：上证路演中心网络互动 三、参加人员 公司参加本次说明会人员包括： 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）已于 2025 年 4 月 29 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-038 上海奥浦迈生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025 年 5 月 9 日 （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，由董事长肖志华先生主持，会议采用现场投票 （二）股东大会召开的地点：上海市浦东新区紫萍路 908 弄 28 号楼 上海奥浦迈 生物科技股份有限公司 五楼公司会议室 和网络投票相结合的方式进行表决。本次会议的召集、召开、表决方式及表决程 序符合《公司法》《证券法》《上海奥浦迈生物科技股份有限公司章程》的相关法 律法规的规定。 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其 持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 55 | | --- | --- | | 普通股股东人数 | 55 | | ...

http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 FANGDA PARTNERS 关于上海奥浦迈生物科技股份有限公司 2024 年年度股东大会的法律意见书 致：上海奥浦迈生物科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席上海奥浦迈 生物科技股份有限公司（以下简称"公司"）2024 年年度股东大会（以下简称"本 次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集会议人员 的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in the culture medium segment shows impressive growth, with a continued validation of the volume logic [7] - The revenue for 2024 is projected to be 2.97 billion yuan, representing a year-on-year increase of 22.26%, while the net profit attributable to the parent company is expected to be 210.5 million yuan, a decrease of 61.04% [7] - The company is entering a harvest period as the culture medium business maintains high growth, with a strong order backlog and a significant increase in clinical trial projects [7] Financial Summary - Total revenue (in million yuan) is forecasted to grow from 297.24 in 2024 to 655.77 in 2027, with year-on-year growth rates of 22.26%, 31.41%, 32.64%, and 26.57% respectively [1][8] - The net profit attributable to the parent company is expected to recover from 21.05 million yuan in 2024 to 140.94 million yuan in 2027, with a notable increase of 215.86% in 2025 [1][8] - The latest diluted EPS is projected to rise from 0.19 yuan in 2024 to 1.24 yuan in 2027, reflecting the company's growth trajectory [1][8] Business Segments - The culture medium business achieved revenue of 244 million yuan in 2024, a growth of 44.0%, with CHO culture medium revenue at 199 million yuan, up by 49.0% [7] - The CDMO business faced challenges with a revenue decline of 25.7% in 2024, but showed signs of recovery with a 27.1% increase in Q1 2025 [7] - The company has a strong pipeline with 258 confirmed drug development projects utilizing its cell culture products, indicating robust future demand [7]

Core Viewpoint - The company reported a revenue increase of 4.98% year-on-year for Q1 2025, driven by growth in its core cell culture products and CDMO services, while also addressing asset impairment provisions and ongoing major asset restructuring plans [5][6][22][31]. Financial Performance - The company achieved operating revenue of 83.68 million yuan in Q1 2025, a 4.98% increase compared to the same period last year [5]. - Main business revenue reached 83.56 million yuan, reflecting a growth of 4.99% year-on-year [5]. - The CDMO service revenue grew significantly by 27.11% compared to the previous year [6]. Business Segments - The cell culture products segment saw a steady revenue increase of 2.50% year-on-year, remaining a key revenue driver for the company [5]. - The company has 258 confirmed drug development pipelines utilizing its cell culture products, with a notable increase in clinical trial stages [6]. Cash Flow and Efficiency - Customer payment amounts increased by 47.73% year-on-year, indicating improved cash flow and operational efficiency [7]. - The company implemented measures to enhance credit policies and collection mechanisms, resulting in faster fund turnover [7]. Quality Management - The company successfully passed the ISO 9001:2015 quality management system audit with zero non-conformities, demonstrating its commitment to high-quality standards [8]. - The company is also undergoing a Qualified Person (QP) audit to ensure compliance with EU GMP regulations, with expectations to receive the QP compliance statement in Q2 2025 [8]. Asset Impairment - The company plans to recognize a total asset impairment provision of 4.2174 million yuan for Q1 2025, including credit impairment losses of 3.0401 million yuan and inventory impairment losses of 1.1773 million yuan [22][24][26][27]. Major Asset Restructuring - The company is planning a major asset restructuring by acquiring 100% equity of Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment [31]. - The restructuring is expected to meet the criteria for significant asset restructuring as per regulatory standards, with no change in the controlling shareholder or actual controller [31].

Summary of the Conference Call for Aopumai Company Overview - **Company**: Aopumai - **Industry**: Biotechnology, specifically focusing on cell culture products and services Key Financial Metrics - **Q1 2025 Revenue**: 83.68 million yuan, a year-on-year increase of 4.98% [2][5] - **Net Profit**: 14.66 million yuan, a year-on-year decrease of 25% due to increased R&D expenses leading to higher taxes [2][5] - **R&D Expenses**: Increased by 56.51% to 12.11 million yuan, primarily for the U.S. subsidiary's R&D lab [2][5] - **Cash Flow**: Net cash inflow from operating activities was 43.30 million yuan, a significant increase of 665% year-on-year [5] Market Performance - **Domestic Market Growth**: Approximately 3% [2][9] - **International Market Growth**: Over 8% [2][9] - **Order Volume**: Cultivation medium orders doubled year-on-year, reaching a historical high [2][9] Strategic Developments - **New Facilities**: The Taicang factory's agarose production line and liquid culture medium filling line have commenced trial operations, enhancing production capabilities [2][6] - **U.S. Operations**: The U.S. subsidiary's lab is operational, accelerating factory construction to address trade challenges [2][6] - **Acquisition Plans**: Actively pursuing the acquisition of Tencent's project to enhance cell culture product and service integration [2][6] R&D and Product Development - **Product Focus**: Continued emphasis on developing innovative products such as diagnostic reagents, agarose, and cell culture media [2][10] - **Clinical Projects**: 258 drug pipelines are utilizing Aopumai's culture media, with 11 new pipelines added in Q1 [3][17] Profitability and Cost Management - **Gross Margin**: Comprehensive gross margin decreased by 5.9% year-on-year but improved by 19% quarter-on-quarter [4][11] - **Management Expenses**: Significant reduction in management expense ratio, indicating improved operational efficiency [4][11] Future Outlook - **Growth Potential**: Aopumai is positioned for rapid growth despite global uncertainties, with a focus on expanding international operations, particularly in the U.S. [7][21] - **Customer Payment Improvement**: Customer payment amounts increased by 44.73% year-on-year, indicating improved cash flow and customer stability [7][8] - **Market Expectations**: Anticipated growth in overseas markets, with a goal to exceed domestic market value [20][21] Risks and Challenges - **Global Economic Uncertainty**: Ongoing trade tensions and tariff issues pose potential risks to future business development [8][21] - **CDMO Business Recovery**: The CDMO business is gradually recovering but still faces challenges due to the need for commercial orders to reach a breakeven sales scale of approximately 100 million yuan [4][12][13] Conclusion Aopumai is navigating a complex market landscape with strategic investments in R&D and facility expansion, while also addressing challenges posed by global economic conditions. The company remains optimistic about future growth and is committed to enhancing its product offerings and market presence.